m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05087
 [1]
Non-coding RNA Dubr YTHDF1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification Tau Tau YTHDF1 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 1 (YTHDF1) READER
 Regulator Info 
m6A Target Microtubule-associated protein tau (TAU)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator DPPA2 upstream binding RNA (DUBR) LncRNA View Details
Regulated Target YTH domain-containing family protein 1 (YTHDF1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary m6A-modified lincRNA DUBR is required for neuronal development by stabilizing YTHDF1 and facilitating mRNA translation.Dubr interacts with m6A-binding proteins, the YTHDF1/3 complex, through its m6A motifs to protect YTHDF1/3 from degradation via the proteasome pathway. Furthermore, Microtubule-associated protein tau (TAU) and Calmodulin are regulated by YTHDF1/3 and m6A-modified Dubr.
In-vitro Model
 Neuro-2a Mouse neuroblastoma Mus musculus CVCL_0470
ND7/23
 N.A. Mus musculus CVCL_4259
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Microtubule-associated protein tau (TAU) 21 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Davunetide Phase 3 [2]
Synonyms
NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0V1FF
 Compound Name TRx0237 Phase 3 [3]
Synonyms
951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23651551
TTD: D5FSV8
 Compound Name LMT-X Phase 3 [4]
Synonyms
Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05XDZ
 Compound Name E2814 Phase 2/3 [5]
External Link
TTD: DQ02VJ
 Compound Name PBT-2 Phase 2 [6]
Synonyms
AD/HD therapy, Prana; Alzheimers/Huntingtons disease therapy (chelating agent), Prana
    Click to Show/Hide
MOA Modulator
External Link
CID: 10016012
TTD: D00GXL
DrugBank: DB05565
 Compound Name RG6100 Phase 2 [7]
MOA Inhibitor
External Link
TTD: D01EJG
 Compound Name Tau-binding PET tracer Phase 2 [2]
Synonyms
T-777; T-807; T-808; Tau-binding PET tracer (Alzheimer disease); Tau-binding PET tracer (Alzheimer disease), Siemens
    Click to Show/Hide
MOA Modulator
External Link
CID: 71059746
TTD: D02IJA
DrugBank: DB15033
 Compound Name BIIB092 Phase 2 [7]
MOA Inhibitor
External Link
TTD: D0I8FS
 Compound Name JNJ-63733657 Phase 2 [8]
External Link
TTD: DJH56Z
 Compound Name Semorinemab Phase 2 [9]
Synonyms
RO7105705
    Click to Show/Hide
External Link
TTD: D96UBZ
 Compound Name Bepranemab Phase 2 [10]
Synonyms
RG6416
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: DK6BL5
 Compound Name LY3303560 Phase 1 [11]
External Link
TTD: D02DZK
 Compound Name PTI-80 Phase 1 [12]
MOA Inhibitor
External Link
TTD: D0P8YJ
 Compound Name PRX-005 Phase 1 [13]
MOA Inhibitor
External Link
TTD: DMSL68
 Compound Name APNmAb005 Phase 1 [14]
MOA Inhibitor
External Link
TTD: DO31MK
 Compound Name BEY2153 Phase 1 [15]
MOA Inhibitor
External Link
TTD: DFM7X6
 Compound Name Lu AF87908 Phase 1 [16]
External Link
TTD: DPU26Z
 Compound Name NI-105 Investigative [2]
Synonyms
Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics
    Click to Show/Hide
MOA Modulator
External Link
CID: 10065825
TTD: D03LGX
 Compound Name AL-408 Investigative [2]
Synonyms
AL-108 analog (neurodegenerative diseases), Allon
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0D2GZ
 Compound Name BLV-0703 Investigative [2]
Synonyms
BLV-200703; KTP-NH2; TAU-targeting compound (CNS disorders), Bioalvo
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0T9PL
 Compound Name PMID28766366-Compound-Scheme22Middle Patented [17]
External Link
TTD: D0I3LY
References
Ref 1 m(6)A-modified lincRNA Dubr is required for neuronal development by stabilizing YTHDF1/3 and facilitating mRNA translation. Cell Rep. 2022 Nov 22;41(8):111693. doi: 10.1016/j.celrep.2022.111693.
Ref 2 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
Ref 3 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
Ref 4 Clinical pipeline report, company report or official report of TauRx.
Ref 5 Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
Ref 6 PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.
Ref 9 Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
Ref 10 Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
Ref 11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 12 Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.
Ref 13 Clinical pipeline report, company report or official report of Prothena
Ref 14 Clinical pipeline report, company report or official report of Aprinoia Therapeutics
Ref 15 Clinical pipeline report, company report or official report of BeyondBio
Ref 16 Clinical pipeline report, company report or official report of Lundbeck
Ref 17 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.